Erratum: SH2 Modified STAT1 Induces HLA-I Expression and Improves IFN-γ Signaling in IFN-α Resistant HCV Replicon Cells (PLoS ONE (2010) 5:9 (e13117) DOI: 10.1371/journal.pone.0013117);SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-14

  Poat, Bret ^a   Hazari, Sidhartha ^a   Chandra, Partha K ^a   Gunduz, Feyza ^a,b   Balart, Luis A ^b   Alvarez, Xavier ^c   Dash, Srikanta ^a,b  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; HLA A1 ANTIGEN; PHENYLALANINE; PROTEIN SH2; STAT1 PROTEIN; STAT2 PROTEIN; TYROSINE; ANTIVIRUS AGENT; HLA ANTIGEN; STAT1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; GENE TRANSLOCATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PLASMID; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REPLICON; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; CELL LINE; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION; GENETICS; HEPATITIS C; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SRC HOMOLOGY DOMAIN; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENE EXPRESSION; HEPACIVIRUS; HEPATITIS C; HLA ANTIGENS; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; PHOSPHORYLATION; REPLICON; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; STAT1 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

EID: 77958541840     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0266497     Document Type: Erratum

References (43)

1. Sy T, Jamal M (2006) Epidemiology of Hepatitis C virus infection. Int J Med Sci 3: 41-46.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffrman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
3. Manns M, Wedemeyer H, Cornberg M (2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55: 1350-1359.
4. Brown RS, Jr., Gaglio PJ (2003) Scope of worldwide hepatitis C problem. Liver Transpl 9: S10-S13.
5. Kim WR (2002) The burden of hepatitis C in the United States. Hepatology 36 (Suppl): S30-S34.
6. Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809.
7. Pestka S (2000) The human interferon alpha species and receptors. Biopolymers 55: 254-287.
8. Melen K, Keskinen P, Lehtonen A, Julkunen I (2000) Interferon-induced gene expression and signaling in human hepatoma cell lines. J Hepatol 33: 764-772.
9. Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, et al. (2002) Interferon alpha activates multiple STAT signals and down regulates C-Met in primary human hepatocytes. Gastroenterology 122: 1020-1034.
10. Gao B, Hong F, Radaeva S (2004) Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 39: 880-890.
11. Decker T, Kovarik P, Meinke A (1997) GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 17: 121-134.
12. Stark GR, Kerr IM, William BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67: 227-264.
13. Vinkemeier U (2004) Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 167: 197-201.
14. Dash S, Prabhu R, Hazari S, Bastian F, Garry R, et al. (2005) Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int 25: 580-594.
15. Guo J, Bichko VV, Seeger C (2001) Effect of alpha interferon on the hepatitis C virus replicon. J Virol 75: 8516-8523.
16. Cheney IW, Lai VCH, Zhong W, Brodhag T, Dempsey S, et al. (2002) Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol 76: 11148-11154.
17. Frese M, Schwarzle V, Barth K, Krieger, Lohmann V, et al. (2002) Interferon-g inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35: 694-703.
18. Trepo C (2000) Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 7: 250-257.
19. Taylor DR, Shi ST, Lai MM (2000) Hepatitis C virus and interferon resistance. Microbes Infect 2: 1743-1756.
20. He Y, Katze MG (2002) To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. Viral Immunol 15: 95-119.
21. Hazari S, Taylor L, Haque S, Garry RF, Florman S, et al. (2007) Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J 4: 89.
22. Hazari S, Chandra PK, Poat B, Datta S, Garry RF, et al. (2010) Impaired antiviral activity of interferon alpha in Huh-7 cells with defective Jak-Stat pathway. Virol J 7: 36.
23. Zhang Y, Takami K, Lo MS, Huang G, Yu Q, et al. (2005) Modification of the STAT1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment. J Biol Chem 280: 34306-34315.
24. Liddle FJ, Alvarez JV, Poli V, Frank DA (2006) Tyrosine phosphorylation is required for funtioncal activation of disulphide-containing constitutive active Stat mutants. Biochemistry 45: 5599-5605.
25. Soza A, Heller T, Ghany M, Lutchman G, Liang TJ, et al. (2005) Pilot study of interferon gamma for hepatitis C. J Hepatol 43: 67-71.
26. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, et al. (1991) High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 13: 327-331.
27. Kumashiro R, Ide T, Sasaki M, Murashima S, Suzuki H, et al. (2002) Interferon-gamma brings additive antiviral environment when combined with interferon alpha in atients with chronic hepatitis C. Hepatol Res 22: 20-26.
28. Bromberg JF, Wrzeszcznska MH, Devgan G, Zhao YH, Pestell RG, et al. (1999) STAT3 as an oncogene. Cells 98: 295-303.
29. Decker T, Kovarik P, Meinke A (1997) GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon cytokine Res 17: 121-134.
30. Zhou F (2009) Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28: 239-260.
31. Zhong M, Henriksen MA, Takeuchi K, Schaefer O, Liu B, et al. (2005) Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci U S A 102: 3966-3971.
32. Lemon SM (2010) Induction and evasion of innate antiviral response by hepatitis C virus. J Biol Chem 285: 22741-22747.
33. Taniguchi H, Iwasaki Y, Takahashi A, Shimomura H, Moriya A, et al. (2007) Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C. Intervirology 50: 32-39.
34. Morita K, Tanaka K, Saito S, Kitamura T, Kondo M, et al. (1998) Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J Clin Gastroenterol 26: 135-140.
35. Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, et al. (2004) Type 1 interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral hepat 11: 136-140.
36. Meng XW, Chi BR, Chen LG, Zhang LL, Zhuang Y, et al. (2005) Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus- related chronic liver disease. World J Gastroenterol 11: 3962-3965.
37. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, et al. (2009) Variants in Interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C Antiviral Long-term treatment against Cirrhosis trial. Hepatology 49: 1847-1858.
38. Liu J, HuangFu WC, Kumar SKG, Qian J, Caset JP, et al. (2009) Virus induced unfolded protein response attenuates antiviral defenses via phosphorylationdependent degradation of the type I interferon receptor. Cell Host Microbe 5: 72-83.
39. Chen L, Borozan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders from non-responders in treatment of chronic hepatitis C viral infection. Gastroneterology 128: 1437-1444.
40. Chen L, Borozan I, Sun J, Guindi M, Fischer S, et al. (2010) Cell-type specific gene expression signature in liver underlines response to interferon therapy in chronic hepatitis C virus infection. Gastroenterology 138: 1123-1133.
41. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039.
42. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, et al. (2007) Systemic and specific delivery of small interfering RNA to the liver mediated by apolipoprotein A-1. Mol Ther 15: 1145-1152.
43. Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, et al. (2009) Development of lipoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17: 872-879.